Letairis™ (ambrisentan), FDA-Approved for Pulmonary Arterial Hypertension
Filed in archive News , Treatment on June 17, 2007
Manufactured by Gilead Sciences, Inc., Letairisâ„¢ (ambrisentan) has recently been approved by the FDA for the treatment of pulmonary arterial hypertension.
Pulmonary arterial hypertension is a rare, life-threatening condition characterized by continuous high blood pressure within the arteries of the lungs.
[In pulmonary arterial hypertension, the small arteries in the lungs become narrowed or blocked, and the heart must work harder to pump the blood through them.
Over time, the overworked heart muscle may become weak and lose its ability to pump enough blood through the lungs.
Symptoms include shortness of breath, fatigue, chest pain, dizzy spells and fainting. About 100,000 people in the United States have pulmonary arterial hypertension.]
According to John Jenkins, M.D., director of FDA's Office of New Drugs:
"Letairis represents a valuable addition to the treatment alternatives for this orphan disease. Letairis is similar to an existing drug, but offers the potential for fewer drug interactions."
Not previously approved in the Unites States, Letairisâ„¢ was granted a priority review by FDA and was granted orphan drug status because it treats a rare disease and meets other criteria.
Letairisâ„¢ will be available in five-milligram and 10-milligram once-daily tablets.
Find more details from the press releases at FDA and Gilead Sciences, Inc.

Tags: Letairis™ ambrisentan pulmonary arterial hypertension 2007 arterial+hypertension pulmonary+arteria
Vote for Letairis™ (ambrisentan), FDA-Approved for Pulmonary Arterial Hypertension:
|
Rating: 5.40 out of 5 vote(s) cast.
|
Response from:
Md.Abdul Khalid Ben Khaleque
(08/08/10 5:18pm)
www.medicalnewstoday.com
Response from:
Nr C Kemp
(02/13/11 2:31am)
General interest and of updates.
Thank you! (ck3klm)
Thank you! (ck3klm)
Response from:
Trusted.MD Network
Manufactured by Gilead Sciences, Inc., Letairis™ (ambrisentan) has recently been approved by the FDA for the treatment of pulmonary arterial hypertension. Pulmonary arterial hypertension is a rare, life-threatening condition characterized by continuous
Most Popular
Allergies
Alzheimer's Disease
Arthritis
Bacteria and Bacterial Infections
Best of
Blog Carnivals
Bone Health
Cancer
Cardiovascular Health
Cases
CFS
Consumer Alert
Controversies
Dental Health
Diabetes
Diagnostics
Diarrhea
Did you know
Diet
Dietary Supplements and Vitamins
